Enumera Molecular is a life science tools company based in Ann Arbor, Michigan, focused on developing a scalable biomolecule assessment platform aimed at enhancing clinical diagnostics. The company's innovative platform simplifies complex molecular testing, facilitating lower-cost and rapid clinical liquid biopsy tests. By transforming the landscape of clinical molecular testing, Enumera Molecular provides physicians with a more actionable tool, ultimately improving patient care through more efficient diagnostic processes.
Akadeum Life Sciences, Inc. is a life sciences company headquartered in Ann Arbor, Michigan, that specializes in manufacturing microbubble cell separation products. Founded in 2014, the company focuses on isolating mammalian and bacterial cells from complex mixtures, offering a range of products including T cell and B cell isolation kits for human and mouse cells. Additionally, Akadeum provides depletion microbubbles for red blood cell removal and streptavidin microbubbles for targeting and capturing various biological entities. Its innovative approach utilizes buoyancy-activated cell sorting, which employs microscopic microbubbles to effectively isolate target cells by floating them to the surface of liquid samples. These advancements enable medical practitioners to perform downstream testing and analysis with enhanced efficiency. The company sells its products online and has established a strategic partnership with Agilent Technologies.
Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.
Navv Systems, is a software solutions and platform company that uses Indoor Positioning technology (IPS) to provide traffic control for hospitals, warehouses, manufacturing, and other large, complex organizations.
Fifth Eye Inc., a medical software company, develops a real time analytics system designed to analyze hemodynamic instability in patients. It offers early warning system that continuously forecasts patient trajectory, giving doctors and nurses a heads up about impending trouble hours in advance of other methods. The company's tool provides first score in five minutes with no baseline needed, minute-to-minute continuous patient assessment, advance warning and real-time treatment feedback, and historical trends without the need for electronic health record inputs. The company was formerly known as Trove Analytics, Inc. and changed its name to Fifth Eye Inc. in June 2018. Fifth Eye Inc. was incorporated in 2017 and is based in Ann Arbor, Michigan.
Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.
Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics and clinical research. The company offers a comprehensive range of products, including RNA library kits, amplicon panels, hybridization capture kits, and specialized kits for cancer gene profiling and COVID-19 testing. Swift Biosciences aims to streamline NGS sample preparation processes through innovative reagents and protocols, enhancing the usability of data obtained from sequencing instruments. Its offerings cater to various applications such as whole-genome sequencing, metagenomics, and the analysis of circulating tumor cells. The company operates through a network of distributors across the Asia Pacific, Europe, the Middle East, and South America, and was incorporated in 2009.
ConcertoCare provides healthcare services primarily to dual-eligible patients enrolled in Medicare and Medicaid, as well as those with complex medical needs. The company focuses on addressing critical vulnerabilities faced by these patients and health plans by offering personalized primary care, chronic condition management, and support for transitions between various care settings. Additionally, ConcertoCare delivers medical, social, and logistical assistance to enhance patient outcomes. Founded in 2004 and based in Aliso Viejo, California, the company operates care centers in locations including Renton, Washington, and several cities in Michigan. The name Concerto reflects its holistic approach to healthcare, emphasizing collaboration among patients, providers, and health plans to ensure coordinated care that respects the dignity and health of each individual.
Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.
ArborMetrix, Inc. specializes in data analytics and technology solutions aimed at enhancing outcomes and advancing research within the healthcare industry. The company offers a platform that facilitates data collection and integration, performance measurement, and analytics, along with comprehensive database administration. Its solutions include EpisodeMetrix, which analyzes episode costs to help healthcare payers and providers optimize networks and manage care costs, and RegistryMetrix, designed for creating tailored clinical registries. Additionally, SurgicalMetrix provides insights into the performance of surgical groups by integrating various clinical and operational data. ArborMetrix’s offerings also encompass clinical quality improvement, patient and provider engagement, value-based reimbursement, and clinical research. The company serves a diverse range of clients, including specialty societies, medical device manufacturers, pharmaceutical companies, and health systems across the United States. Founded in 2011, ArborMetrix is headquartered in Ann Arbor, Michigan.
Delphinus Medical Technologies, Inc. is a medical imaging company founded in 2009 and headquartered in Plymouth, Michigan, with a satellite office in Sunnyvale, California. The company specializes in the development and commercialization of SoftVue, a circular array transducer technology designed for ultrasound imaging of the entire breast. This innovative system allows for three-dimensional and tomographic imaging, enabling medical professionals to differentiate between benign and malignant masses, assess breast cancer risks, and diagnose breast diseases. SoftVue offers a non-invasive and comfortable screening experience for women, eliminating concerns about radiation. Delphinus Medical Technologies serves hospitals and imaging clinics both in the United States and internationally, focusing on improving early detection and monitoring of breast cancer.
NeuMoDx Molecular, Inc. is a molecular diagnostics company focused on developing solutions for molecular diagnostic testing in hospital and clinical reference laboratories. Established in 2012 and based in Ann Arbor, Michigan, the company was formerly known as Molecular Systems Corporation before rebranding in April 2013. As of September 2020, NeuMoDx operates as a subsidiary of QIAGEN N.V. Its innovative products aim to enhance the efficiency and accuracy of molecular testing, contributing to better patient outcomes in various healthcare settings.
Delphinus Medical Technologies, Inc. is a medical imaging company founded in 2009 and headquartered in Plymouth, Michigan, with a satellite office in Sunnyvale, California. The company specializes in the development and commercialization of SoftVue, a circular array transducer technology designed for ultrasound imaging of the entire breast. This innovative system allows for three-dimensional and tomographic imaging, enabling medical professionals to differentiate between benign and malignant masses, assess breast cancer risks, and diagnose breast diseases. SoftVue offers a non-invasive and comfortable screening experience for women, eliminating concerns about radiation. Delphinus Medical Technologies serves hospitals and imaging clinics both in the United States and internationally, focusing on improving early detection and monitoring of breast cancer.
ArborMetrix, Inc. specializes in data analytics and technology solutions aimed at enhancing outcomes and advancing research within the healthcare industry. The company offers a platform that facilitates data collection and integration, performance measurement, and analytics, along with comprehensive database administration. Its solutions include EpisodeMetrix, which analyzes episode costs to help healthcare payers and providers optimize networks and manage care costs, and RegistryMetrix, designed for creating tailored clinical registries. Additionally, SurgicalMetrix provides insights into the performance of surgical groups by integrating various clinical and operational data. ArborMetrix’s offerings also encompass clinical quality improvement, patient and provider engagement, value-based reimbursement, and clinical research. The company serves a diverse range of clients, including specialty societies, medical device manufacturers, pharmaceutical companies, and health systems across the United States. Founded in 2011, ArborMetrix is headquartered in Ann Arbor, Michigan.
Fidelis SeniorCare, Inc., a managed care company, develops and administers health plans for assisted living residents in Michigan, North Carolina, and Texas. The company offers Medicare advantage special needs plans to cover the health needs of seniors living in nursing homes and assisted living communities; and individuals who require specialized healthcare. Its plans cover on-site primary care team visits, part D prescription drugs, monitoring and managing prescribed medications, transportation to the hospital or physician’s office, and skilled nursing services during a covered Medicare stay; preventive care, screening, vision/dental/hearing, and podiatry services; and emergency room, ambulance, and urgent care services. The company was founded in 2004 and is based in Schaumburg, Illinois.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath⢠Closed IV Catheter System, in 2012.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath⢠Closed IV Catheter System, in 2012.
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath⢠Closed IV Catheter System, in 2012.
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.
Delphinus Medical Technologies, Inc. is a medical imaging company founded in 2009 and headquartered in Plymouth, Michigan, with a satellite office in Sunnyvale, California. The company specializes in the development and commercialization of SoftVue, a circular array transducer technology designed for ultrasound imaging of the entire breast. This innovative system allows for three-dimensional and tomographic imaging, enabling medical professionals to differentiate between benign and malignant masses, assess breast cancer risks, and diagnose breast diseases. SoftVue offers a non-invasive and comfortable screening experience for women, eliminating concerns about radiation. Delphinus Medical Technologies serves hospitals and imaging clinics both in the United States and internationally, focusing on improving early detection and monitoring of breast cancer.
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.
HealthMedia, founded in 1998 by Dr. Victor Strecher, specializes in scalable behavior change interventions aimed at health and wellness, disease management, and medication compliance. The company has developed innovative programs that replicate the benefits of health coaching sessions without the need for an actual coach. Its unique methodology and technology deliver effective outcomes similar to traditional health coaching while leveraging the scalability of web content. HealthMedia also creates specialized programs for pharmaceutical companies and medical device manufacturers, addressing a range of health issues, including drug and alcohol addiction, mental illness, and chronic conditions such as hypertension and heart disease.
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.
Asterand Bioscience is the leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success. Asterand Bioscience has a well-established human tissue heritage, having been formed in 2006 through the merger of Asterand (founded 2000), a human tissue biorepository and Pharmagene (founded 1996) a human tissue-based drug discovery company. With this background and capability in human tissue procurement, characterization and research tools, Asterand Bioscience is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical, biotechnology and diagnostic companies, as well as academia. From our offices in Detroit, MI and Royston, U.K., our employees focus on providing services and products to accelerate drug discovery research from target identification through compound evaluation and drug safety.